

Supplementary Table 2. Formal extrapyramidal symptom rating scale scores for patients with MDD receiving open-label adjunctive brexpiprazole 0.5–3 mg/day

	Safety population		
	Mean (SD) at baseline (n=2,938)	Mean (SD) change from baseline to Week 52 (OC) (n=770)	Mean (SD) change from baseline to Week 52 (LOCF) (n=2,915)
SAS Total score	0.16 (0.58)	-0.05 (0.93)*	0.01 (0.78)
BARS Global score	0.09 (0.36)	-0.07 (0.43)	0.00 (0.44)
AIMS Movement rating score [†]	0.02 (0.26)	-0.03 (0.53)	0.00 (0.37) [‡]

AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; LOCF, last observation carried forward; MDD, major depressive disorder; OC, observed cases; SAS, Simpson–Angus Scale; SD, standard deviation.

*n=769.

[†]AIMS Movement rating score was defined as the sum of items 1–7 (facial and oral, extremity, and trunk movements).

[‡]n=2,880.